Basis of Presentation and Summary of Significant Accounting Policies (Tables)
|
6 Months Ended |
Jun. 30, 2020 |
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
|
Schedule of Revenue by Source |
The following table represents disaggregation of royalties, Captisol, service revenue and contract revenue (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended |
|
|
|
|
Six months ended |
|
|
|
|
June 30, |
|
|
|
|
June 30, |
|
|
|
|
2020 |
|
2019 |
|
|
2020 |
|
2019 |
Royalties |
|
|
|
|
|
|
|
|
|
|
Kyprolis |
$ |
5,481 |
|
|
$ |
4,882 |
|
|
|
$ |
9,886 |
|
|
$ |
8,715 |
|
|
Evomela |
1,199 |
|
|
1,144 |
|
|
|
2,775 |
|
|
2,055 |
|
|
Other |
501 |
|
|
600 |
|
|
|
1,085 |
|
|
1,201 |
|
|
Promacta |
— |
|
|
— |
|
|
|
— |
|
|
14,193 |
|
|
|
$ |
7,181 |
|
|
$ |
6,626 |
|
|
|
$ |
13,746 |
|
|
$ |
26,164 |
|
|
|
|
|
|
|
|
|
|
|
Captisol |
|
$ |
24,468 |
|
|
$ |
8,549 |
|
|
|
$ |
45,577 |
|
|
$ |
17,508 |
|
|
|
|
|
|
|
|
|
|
|
Service Revenue |
|
$ |
4,582 |
|
|
$ |
4,559 |
|
|
|
$ |
7,939 |
|
|
$ |
8,442 |
|
|
|
|
|
|
|
|
|
|
|
Contract Revenue |
|
|
|
|
|
|
|
|
|
|
License Fees |
$ |
660 |
|
|
$ |
1,990 |
|
|
|
$ |
1,635 |
|
|
$ |
2,840 |
|
|
Milestone |
3,472 |
|
|
2,497 |
|
|
|
3,806 |
|
|
12,751 |
|
|
Other |
1,057 |
|
|
766 |
|
|
|
1,878 |
|
|
766 |
|
|
|
$ |
5,189 |
|
|
$ |
5,253 |
|
|
|
$ |
7,319 |
|
|
$ |
16,357 |
|
|
|
|
|
|
|
|
|
|
|
Total |
|
$ |
41,420 |
|
|
$ |
24,987 |
|
|
|
$ |
74,581 |
|
|
$ |
68,471 |
|
|
Schedule of Short-Term Investments |
Our investments, excluding investment in Viking, consist of the following at June 30, 2020 and December 31, 2019 (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
June 30, 2020 |
|
|
|
|
|
|
|
December 31, 2019 |
|
|
|
|
|
|
|
Amortized cost |
|
Gross unrealized gains |
|
Gross unrealized losses |
|
Estimated fair value |
|
Amortized cost |
|
Gross unrealized gains |
|
Gross unrealized losses |
|
Estimated fair value |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-term investments |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Bank deposits |
$ |
269,114 |
|
|
$ |
221 |
|
|
$ |
(56) |
|
|
$ |
269,279 |
|
|
$ |
411,690 |
|
|
$ |
188 |
|
|
$ |
(3) |
|
|
$ |
411,875 |
|
Corporate bonds |
55,380 |
|
|
125 |
|
|
(94) |
|
|
55,411 |
|
|
63,818 |
|
|
161 |
|
|
— |
|
|
63,979 |
|
Commercial paper |
163,590 |
|
|
134 |
|
|
— |
|
|
163,724 |
|
|
210,525 |
|
|
43 |
|
|
(16) |
|
|
210,552 |
|
Corporate equity securities |
4,506 |
|
|
634 |
|
|
(2,484) |
|
|
2,656 |
|
|
4,506 |
|
|
416 |
|
|
(1,850) |
|
|
3,072 |
|
Mutual fund |
151,223 |
|
|
— |
|
|
(97) |
|
|
151,126 |
|
|
250,635 |
|
|
— |
|
|
(249) |
|
|
250,386 |
|
Warrants |
— |
|
|
177 |
|
|
— |
|
|
177 |
|
|
— |
|
|
125 |
|
|
— |
|
|
125 |
|
|
$ |
643,813 |
|
|
$ |
1,291 |
|
|
$ |
(2,731) |
|
|
$ |
642,373 |
|
|
$ |
941,174 |
|
|
$ |
933 |
|
|
$ |
(2,118) |
|
|
$ |
939,989 |
|
|
Schedule of Available-for-Sale Debt Securities |
The following table summarizes our available-for-sale debt securities by contractual maturity (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
June 30, 2020 |
|
|
|
Amortized Cost |
|
Fair Value |
Within one year |
$ |
414,505 |
|
|
$ |
414,905 |
|
After one year through five years |
73,579 |
|
|
73,509 |
|
After five years |
— |
|
|
— |
|
Total |
$ |
488,084 |
|
|
$ |
488,414 |
|
The following table summarizes our available-for-sale debt securities in an unrealized loss position (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Less than 12 months |
|
|
|
12 months or greater |
|
|
|
Total |
|
|
|
Gross Unrealized Losses |
|
Estimated Fair Value |
|
Gross Unrealized Losses |
|
Estimated Fair Value |
|
Gross Unrealized Losses |
|
Estimated Fair Value |
June 30, 2020 |
|
|
|
|
|
|
|
|
|
|
|
Bank deposits |
$ |
(56) |
|
|
$ |
30,015 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
(56) |
|
|
$ |
30,015 |
|
Corporate bonds |
(94) |
|
|
16,022 |
|
|
— |
|
|
— |
|
|
(94) |
|
|
16,022 |
|
Total |
$ |
(150) |
|
|
$ |
46,037 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
(150) |
|
|
$ |
46,037 |
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31, 2019 |
|
|
|
|
|
|
|
|
|
|
|
Bank deposits |
$ |
(3) |
|
|
$ |
58,584 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
(3) |
|
|
$ |
58,584 |
|
Commercial paper |
(16) |
|
|
79,363 |
|
|
— |
|
|
— |
|
|
(16) |
|
|
79,363 |
|
Total |
$ |
(19) |
|
|
$ |
137,947 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
(19) |
|
|
$ |
137,947 |
|
|
Schedule of Goodwill and Other Identifiable Intangible Assets |
Goodwill and other identifiable intangible assets consist of the following (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
June 30, |
|
December 31, |
|
2020 |
|
2019 |
Goodwill |
$ |
103,369 |
|
|
$ |
95,229 |
|
Definite lived intangible assets |
|
|
|
Complete technology |
244,513 |
|
|
242,813 |
|
Less: accumulated amortization(1)
|
(57,053) |
|
|
(50,203) |
|
Trade name |
2,642 |
|
|
2,642 |
|
Less: accumulated amortization |
(1,246) |
|
|
(1,180) |
|
Customer relationships |
40,700 |
|
|
29,600 |
|
Less: accumulated amortization |
(14,261) |
|
|
(13,224) |
|
Total goodwill and other identifiable intangible assets, net |
$ |
318,664 |
|
|
$ |
305,677 |
|
|
|
|
|
(1) accumulated amortization for complete technology includes immaterial amount of foreign currency translation adjustments for the complete technology acquired from the Vernalis acquisition.
|
|
|
|
|
Schedule of Commercial License Rights |
Commercial license and other economic rights consist of the following (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
June 30, 2020 |
|
|
|
|
|
December 31, 2019 |
|
|
|
|
|
|
Gross |
|
Adjustments(1)
|
|
Net |
|
Gross |
|
Adjustments(2)
|
|
Net |
Aziyo and CorMatrix |
|
$ |
17,696 |
|
|
$ |
(9,698) |
|
|
$ |
7,998 |
|
|
$ |
17,696 |
|
|
$ |
(5,500) |
|
|
$ |
12,196 |
|
Palvella |
|
10,000 |
|
|
(10,000) |
|
|
— |
|
|
10,000 |
|
|
(7,492) |
|
|
2,508 |
|
Selexis and Dianomi |
|
10,602 |
|
|
(7,994) |
|
|
2,608 |
|
|
10,602 |
|
|
(5,216) |
|
|
5,386 |
|
Total |
|
$ |
38,298 |
|
|
$ |
(27,692) |
|
|
$ |
10,606 |
|
|
$ |
38,298 |
|
|
$ |
(18,208) |
|
|
$ |
20,090 |
|
(1) Amounts represent accumulated amortization to principal or research and development expenses of $21.7 million and credit loss adjustments of $6.0 million as of June 30, 2020.
(2) Amounts represent accumulated amortization to principal or research and development expenses as of December 31, 2019.
|
Schedule of Accrued Liabilities |
Accrued liabilities consist of the following (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
June 30, |
|
December 31, |
|
|
2020 |
|
2019 |
Compensation |
|
$ |
3,457 |
|
|
$ |
1,986 |
|
Professional fees |
|
964 |
|
|
1,135 |
|
Amounts owed to former licensees |
|
413 |
|
|
381 |
|
Royalties owed to third parties |
|
1,038 |
|
|
— |
|
Return reserve |
|
2,899 |
|
|
3,027 |
|
Current operating lease liabilities |
|
1,728 |
|
|
1,242 |
|
Accrued interest |
|
471 |
|
|
690 |
|
Other |
|
1,858 |
|
|
1,375 |
|
Total accrued liabilities
|
|
$ |
12,828 |
|
|
$ |
9,836 |
|
|
Schedule of Accounting for Share-Based Compensation |
The following table summarizes share-based compensation expense recorded as components of research and development expenses and general and administrative expenses for the periods indicated (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended |
|
|
|
Six months ended |
|
|
|
|
|
|
|
|
|
|
|
June 30, |
|
|
|
June 30, |
|
|
|
|
|
|
|
|
|
|
|
2020 |
|
2019 |
|
2020 |
|
2019 |
|
|
|
|
|
|
|
|
SBC - Research and development expenses |
$ |
3,019 |
|
|
$ |
2,528 |
|
|
$ |
5,416 |
|
|
$ |
4,655 |
|
|
|
|
|
|
|
|
|
SBC - General and administrative expenses |
4,340 |
|
|
4,043 |
|
|
7,596 |
|
|
7,263 |
|
|
|
|
|
|
|
|
|
|
$ |
7,359 |
|
|
$ |
6,571 |
|
|
$ |
13,012 |
|
|
$ |
11,918 |
|
|
|
|
|
|
|
|
|
|
Schedule of Fair-Value Options Awarded to Employees and Directors |
The fair-value for options that were awarded to employees and directors was estimated at the date of grant using the Black-Scholes option valuation model with the following weighted-average assumptions:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended |
|
|
|
|
Six months ended |
|
|
|
June 30, |
|
|
|
|
June 30, |
|
|
|
2020 |
|
2019 |
|
|
2020 |
|
2019 |
Risk-free interest rate |
0.4% |
|
1.9% |
|
|
1.1% |
|
2.4% |
Dividend yield |
— |
|
— |
|
|
— |
|
— |
Expected volatility |
69% |
|
40% |
|
|
55% |
|
43% |
Expected term |
5.1 |
|
5.9 |
|
|
4.8 |
|
5.2 |
|
Schedule of Computation of Basic and Diluted Earnings per Share |
The following table presents the calculation of weighted average shares used to calculate basic and diluted earnings per share (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended |
|
|
|
|
Six months ended |
|
|
|
June 30, |
|
|
|
|
June 30, |
|
|
|
2020 |
|
2019 |
|
|
2020 |
|
2019 |
Weighted average shares outstanding: |
16,055 |
|
|
19,558 |
|
|
|
16,292 |
|
|
20,000 |
|
Dilutive potential common shares: |
|
|
|
|
|
|
|
|
Restricted stock |
40 |
|
|
— |
|
|
|
— |
|
|
38 |
|
Stock options |
599 |
|
|
— |
|
|
|
— |
|
|
761 |
|
Shares used to compute diluted income per share |
16,694 |
|
|
19,558 |
|
|
|
16,292 |
|
|
20,799 |
|
Potentially dilutive shares excluded from calculation due to anti-dilutive effect |
7,832 |
|
|
7,457 |
|
|
|
8,988 |
|
|
7,243 |
|
|
|
|
|
|
|
|
|
|
|